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Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – 
analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) 
Background  
The ability to predict the survival of patients with platinum resistant/refractory (PRROC) or 
“potentially platinum sensitive” (PPSROC) who have been treated with ≥3 lines of chemotherapy 
(PPS>3) could support physician-patient communication and help guide treatment decisions. The 
inflammation based modified Glasgow Prognostic Score (mGPS) is predictive of survival in patients 
with a wide range of advanced cancers, but has not been evaluated in ROC.  The aim of this study 
was to determine the validity of the mGPS in ROC and investigate its associations with health related 
quality of life (HRQL) and ECOG performance status (PS).   
Methods 
All assessments were performed before starting chemotherapy. The mGPS is based on serum levels 
of C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most).  HRQL was 
measured with the EORTC QLQ C-30 and OV-28.   Χ2 tests for trend were used to examine the 
relationship between HRQL, PS and mGPS.  Cox proportional hazards regression was used to assess 
associations between mGPS, HRQL, clinicopathological factors, and overall survival (OS).  
Results 
Inflammatory markers were available in 516 of 948 patients in the GCIG SBS.  200 (39%) had PPS≥3, 
316 (61%) had PRROC. 282 (55%), 123 (24%), 111 (22%) had an mGPS of 0, 1, 2, respectively.  
Median OS in months was 18.1, 9.6, and 6.6 for mGPS of 0, 1, and 2 respectively.  The mGPS was a 
statistically significant, independent predictor of OS after adjusting for PS and platinum sensitivity 
(p<0.001).  mGPS also remained a significant predictor of OS after adjusting for physical function, 
role function, global health status, abdominal/GI symptoms, and multiple clinicopathologic factors  
(p=0.02). Worse PS and higher mGPS were associated with poorer HRQL (p<0.001).  Higher mGPS 
was associated with worse HRQL, independent of PS.  
Conclusion 
The mGPS is an independent, significant predictor of OS in ROC after adjusting for HRQL and 
clinicopathological factors.  Higher mGPS is associated with worse HRQL independent of PS. The 
mGPS is inexpensive, simple to measure, and suitable for use in routine clinical practice, and to both 
select and stratify participants for clinical trials.   
 
 
 
 
 
 
INTRODUCTION 
Ovarian cancer is the leading cause of gynaecological cancer death in the USA [1].  Most women with 
ovarian cancer have advanced disease at diagnosis, and are treated with surgery and platinum-based 
chemotherapy, but over 80% will experience disease recurrence requiring further therapy. Patients 
diagnosed with recurrent disease  within 6 months of completing platinum-based chemotherapy are 
classified as having platinum-resistant recurrent ovarian cancer (PRROC).[2]. Patients diagnosed with 
recurrent disease more than 6 months after completing platinum-based chemotherapy are classified 
as having “platinum sensitive” recurrent ovarian cancer (PSROC). The overall survival ranges from 
12-18 months in PRROC,[3-8] 2-4 years for PSROC,[2, 9, 10] and gets progressively shorter after 
multiple lines of chemotherapy.  
One of the biggest challenges faced by physicians is selecting patients with ROC who are more likely 
to benefit from further chemotherapy, and in particular, to identify the subgroup of patients with a 
very short survival in whom palliative care might be a better option than chemotherapy, in keeping 
with the ASCO Choosing Wisely campaign. This is particularly important given the discordance in 
understanding of prognosis between physicians and patients[11].  There is a clear need for a 
validated method to predict survival that can be used in clinical practice and help frame the 
important discussion on prognosis and treatment options with patients and families.  This will allow 
patients to make more informed decisions regarding further chemotherapy as well as improve the 
selection and stratification of patients in clinical trials.   
There is mounting evidence that systemic inflammation is associated with clinical decline, increasing 
pain, and a wide range of systemic symptoms in patients with advanced cancers [12-14].  C-reactive 
protein( CRP) has been reported to be both prognostic  of outcomes, and predictive of response to 
chemotherapy, in a range of cancers [15]. CRP and albumin are synthesized by the liver and secreted 
into the circulation with serum levels that are influenced by proinflammatory cytokines such IL1, IL6 
and TNF[16, 17].  CRP has also been combined with other markers of systemic inflammation to 
predict prognosis. The  best described inflammatory score  is the modified Glasgow prognostic 
score(mGPS)[18], which is calculated from  the CRP and serum albumin.   The mGPS is predictive of 
survival in a wide range of advanced cancers [18-20], but to our knowledge has not been validated in 
ROC.   
Health Related Quality of Life (HRQL) is widely accepted to be an important endpoint in cancer 
clinical trials.  HRQL is prognostic in a wide range of advanced cancers [21-26]. There is a good 
rationale to include HRQL together with markers of systemic inflammation in a prognostic score.  
Laird and colleagues recently investigated systemic inflammation and its association with HRQL and 
PS in patients with advanced cancers, of which a small proportion (6%) had gynaecologic cancer [27].  
They reported that higher mGPS and worse PS were associated with worse HRQOL (P < .001), and 
that systemic inflammation was associated with worse HRQOL independent of PS. 
The aim of this study was to determine the validity of the mGPS in recurrent ovarian cancer and its 
relationships with HRQL, and performance status (PS).    
 
METHODS 
Trial Design 
The GCIG SBS is a prospective, observational, cohort study that enrolled women from collaborating 
GCIG clinical trials groups  from 11 countries who: were aged 18 years or older, had PRROC prior to  
starting 2nd or subsequent line chemotherapy or had PPS ROC prior to starting 3rd or subsequent 
lines of chemotherapy.  All participants who had inflammatory markers recorded in their case report 
form were included in the analyses.  Participants completed HRQOL questionnaires before starting 
chemotherapy.  They were required to have a life expectancy of at least 3 months or greater and an 
ECOG PS of 0-3 for inclusion into the study.   
The specific type, doses, duration, and frequency of administration of chemotherapy were at the 
discretion of the treating physician, and all supportive treatment and concomitant medications were 
given as per institutional practice.   
The Study was lead and coordinated by the NHMRC Clinical Trials Centre, University of Sydney in 
collaboration with Australian New Zealand Gynaecological Oncology Group (ANZGOG) and the GCIG 
Symptom Benefit Committee.  The trial was registered on the Australian New Zealand Clinical Trials 
Registry (ANZCTR: 12607000603415).  The Study was performed in accordance to the NHMRC 
Statement on Ethical Conduct in Research Involving Humans and the Declaration of Helsinki. Ethical 
approval was obtained at all participating sites, and all participants provided signed, written, 
informed consent.  
 
Physician assessment of patients 
Physicians assessed participants at baseline and every 3-4 weeks prior to each cycle of 
chemotherapy.  They recorded baseline characteristics, symptoms (symptomatic ascites and 
cramping abdominal pain), and pre-specified laboratory values including haemoglobin, lactate 
dehydrogenase (LDH), platelets, CA125, CA125 velocity, ECOG PS, C-reactive protein (CRP), albumin, 
neutrophil count, and lymphocyte count.  Tumour response was assessed at 6-8 week intervals using 
the same method of assessment throughout the study, at the discretion of the treating physician.  
Clinical benefit was defined as CA125 response, and/or RECIST response, and/or symptomatic 
improvement as reported by the treating physician.   
Modified Glasgow Prognostic Score (mGPS) 
The   serum CRP and albumin concentrations were recorded at baseline before starting 
chemotherapy.  The mGPS is based on serum levels of CRP and albumin, with scores ranging from 0 
to 2 and is calculated as follows: CRP ≤10mg/L = 0; CRP > 10mg/L = 1; CRP>10mg/L and albumin 
<35g/L = 2[14, 22].   
Patient-rated outcomes 
Participants completed HRQL questionnaires at baseline (within 2 weeks before their first cycle of 
chemotherapy), and then every 3 to 4 weeks before each subsequent cycle of chemotherapy, until 
disease progression.  The questionnaires at baseline included the European Organisation for Research 
and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ C-30) and Ovarian Module 
(OV28). The QLQ-C30 includes multi-item scales for global health status and five functional domains 
(physical, role, cognitive, emotional and social) all scored from 0 (worst) to 100 (best); and, six single 
items for symptoms scored from 0 (least) to 100 (worst). The OV28 includes seven multi-item scales 
for abdominal/gastrointestinal symptoms (AGIS), peripheral neuropathy, hormonal, body image, 
attitude to disease/treatment, chemotherapy side effects, and sexuality rated from 0 (worst) to 100 
(least). 
 
Statistical Analysis 
Baseline patient characteristics were summarized using mean (standard deviation) and median 
(range or interquartile range) for continuous variables with normal and skewed distribution, 
respectively. Categorical variables were expressed as frequencies and percentages. Comparisons of 
baseline characteristics between patients with and without a calculable mGPS were based on the 2 
test for categorical variables. Comparisons of continuous variables were performed using t-tests or 
the Wilcoxon rank-sum test for non-normal data. 
Progression-free survival (PFS) and overall survival (OS) were analysed using time-to-event methods.  
Kaplan-Meier curves of PFS and OS by mGPS category were constructed and likewise median PFS/OS 
calculated. Cox proportional hazards regression was used to compute unadjusted hazard ratios (with 
95% confidence intervals) to estimate the effect of mGPS score category on PFS and OS. In addition 
multivariable Cox regression was performed for OS. The effect of mGPS was first assessed after 
adjustment for ECOG PS and type of resistance (sensitive vs resistant/refractory); and then after 
adjustment for HRQL domains and clinicopathological factors. Clinical factors for the latter model 
were selected using backward elimination; candidate variables were those with P<0.05 in univariable 
analyses. The final model included physical functioning, role functioning, global health status, 
abdominal/GI symptoms, haemoglobin, platinum resistance, symptomatic ascites, abdominal 
cramps, platelets, log CA125, neutrophil: lymphocyte ratio<5, BMI and CA125 velocity ≥ 5. 
To examine relationships between HRQL, PS, and mGPS, we used a series of Χ2 tests for trend in 
which HRQL subscales were analysed as discrete categories. 
All statistical inferences were based on two-sided p values, with values <0.05 generally taken to 
indicate statistical significance. To account for the large number of comparisons depicted in Tables 4 
and 5, we used the Bonferroni method to reduce the risk of false positive conclusions by using a 
more stringent criterion for statistical significance, P<0.001. All analyses were done with SAS 
statistical software package, version 9.4 (SAS Institute, Inc., Cary, NC). 
 
RESULTS 
Serum albumin and CRP were available in 516 of 948 (54%) patients enrolled in the GCIG SBS.  
Baseline characteristics are shown in Table 1.  200 (39%) had PPSROC, 316 (61%) had PRROC. The 
mGPS score was 0, 1 or 2 in 282 (55%), 123 (24%), and 111 (22%) patients respectively.  The median 
OS in months was 18.1, 9.6, and 6.6 for mGPS of 0, 1 and 2, respectively.  The median PFS in months 
was 5.3, 3.7, and 2.9 for mGPS of 0, 1 and 2, respectively (Table 2).   
In univariable analysis, mGPS was associated with overall survival in the whole group that had 
inflammatory markers available (p<0.001).  In multivariable analysis, mGPS was a statistically 
significant predictor of OS after adjusting for PS and platinum sensitivity (p<0.001, see table 3).  The 
mGPS was also a statistically significant predictor of OS after adjusting for physical function, role 
function, global health status, abdominal/GI symptoms and the following clinicopathologic factors: 
haemoglobin, platinum resistance, clinician-rated ascites and abdominal cramps, platelets, CA125, 
neutrophil: lymphocyte ratio <5, BMI, CA125 velocity ≥5 (p=0.024, see table 3).  
The associations between HRQL, PS, and mGPS are shown in table 4.  Worse PS and higher mGPS 
were associated with poorer HRQL (p<0.001, see table 4).  Lower GHS was associated higher mGPS 
independent of PS (ie, mGPS 0, 65.3; mGPS 1, 56.1; mGPS 2, 53.1, p<0.001).  This association was 
weaker with role function, physical function (p<0.023), and abdominal/GI symptoms (p=0.05).   
The associations between symptoms, PS, and mGPS are shown in Table 5.  Worse PS and higher 
mGPS were both associated with more severe symptoms (p<0.001 for fatigue, nausea, pain, 
dyspnoea, anorexia).  Worse nausea/vomiting, pain, dyspnoea and appetite loss were associated 
with higher mGPS, even though most patients had a good PS of 0 or 1 (e.g. nausea/vomiting: PS 1, 
mGPS 0, mean domain score 11.3; mGPS 1, mean domain score 12.3, mGPS 2, mean domain score 
23.6, p<0.001; see table 5).   Higher mGPS was associated with worse HRQL independent of PS.  
Kaplan-Meier curves showing OS and PFS by mGPS showed those with higher mGPS had shorter OS 
and PFS (Figure 1).   
 
DISCUSSION 
Our analyses support validity of the mGPS in ROC by demonstrating that it was a significant and 
independent predictor of OS after adjusting for PS and platinum resistance versus sensitivity.  The 
mGPS remained a significant predictor of OS after adjusting for HRQL and multiple clinicopathologic 
factors including physical function, role function, global health status, abdominal/GI symptoms as 
well as haemoglobin, platinum resistance, clinician rated ascites and abdominal cramping, platelet 
count, CA125, neutrophil: lymphocyte<5, Body Mass Index, CA125 velocity≥5. OS and PFS were 
significantly longer in women with lower mGPS (p<0.001), that is, those with less systemic 
inflammation based on baseline levels of serum CRP and albumin.   
Worse PS (<2) and higher mGPS were also both associated with worse HRQL.  Worse GHS was 
associated with higher mGPS even after accounting for PS.  This was also evident in other functional 
domains such as role function and physical function.   In addition, worse PS and higher mGPS were 
associated with worse symptoms (fatigue, nausea, pain, dyspnoea, anorexia).  Worse 
nausea/vomiting, pain, dyspnoea and appetite loss were also associated with a higher mGPS, despite 
89% of patients recorded as having a good PS of 0 or 1.  Higher mGPS was also associated with worse 
HRQL after accounting for PS, and provided additional prognostic information above and beyond 
that provided by PS.   
To the best of our knowledge, this is the first study to test the validity of the mGPS in ROC. Our study 
analysed over 500 women with recurrent ovarian cancer and included those with both platinum 
resistant ROC, and with potentially platinum sensitive ROC treated with at least 3 prior lines of 
chemotherapy.    The mGPS was a significant predictor of OS after adjusting for two of the other 
most clinically relevant prognostic factors in setting: PS and platinum resistance.  
We also investigated the relationships between mGPS,   HRQL, and PS.  There was a positive 
correlation between worse HRQL and higher mGPS, independent of PS. These findings are consistent 
with those from a recent study by Laird et al[27] who  reported that higher mGPS and  lower PS were 
associated with worse HRQL (P < .001). They also noted that systemic inflammation was associated 
with worse quality of life independent of PS suggesting a direct relationship between the two.    
The main strengths of our study are its prospective design, analysis plan, and large sample size, and 
the consistency of our findings regarding the prognostic significance of the mGPS with studies in 
other tumour types [18, 19, 28-30]. The inclusion of women with ROC and ECOG PS 0-3 is likely to 
better reflect “real world” practice than a typical clinical trial.   We found that worse PS and higher 
mGPS were associated with worse HRQL, and that worse PS and higher mGPS were associated with 
worse symptoms.  Higher mGPS was associated with worse HRQL independent of PS.  A possibole 
limitation of this study is that not all women enrolled in GCIG SBS had baseline assessment of CRP 
and albumin as this is not standard of care internationally. However, those who did not have CRP 
and albumin recorded had similar characteristics to those who did.  Further research is needed to 
assess the validity of the mGPS as a prognostic factor in clinical trials with more homogeneous 
characteristics at baseline. In addition, consideration should be given to researching interventions 
designed to modulate the inflammatory response and their effects on symptoms, HRQOL and 
survival.   
PS is widely used to help guide decision making about chemotherapy, but it was developed over 50 
years ago and has several limitations.  It is subject to bias and there is only a moderate level of 
agreement between clinician and patient reported PS [31, 32].  For example, PS rated by clinicians 
was only weakly associated with self-rated PF (Spearman correlation coefficient -0.37) in our study.   
Prognostic scores are not typically used in the clinic to help predict survival of patients with ROC, but 
a simple, readily available score like the mGPS would be applicable to patients with PRROC as well as 
in patients with PPSROC who have had multiple lines of prior therapy. There is good evidence that 
most patients want to be involved in decision making about treatment and involving palliative care 
services towards the end of life. Physician-patient communication has been identified as an 
actionable target for reducing overly aggressive care  when the prognosis is poor[33].  We have 
validated the mGPS in women with ROC and shown that combining the mGPS with other prognostic 
characteristics, such as performance status, and HRQL significantly improves prognostication. The 
mGPS is a simple, objective score that is readily applicable in routine clinical practice and could 
improve discussion and shared decision making about chemotherapy.  It could also be used in 
clinical trials to improve selection and stratification of participants.   
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Table 1. Baseline characteristics 
Characteristic N=516 N (%) 
Age  
<40 12 (2) 
40-49 55 (11) 
50-59 146 (28) 
60-69 174 (34) 
>70 129 (25) 
Lines of previous chemotherapy  
1 104 (20) 
2 193 (37) 
3 114 (22) 
≥4 105 (20) 
ECOG:  
0-1 459 (89) 
≥2 57 (11) 
Cancer-related symptoms present (clinician rated)  388 (75) 
Symptomatic ascites (clinician-rated) 137 (27) 
Crampy abdominal pain or intermittent/incomplete bowel obstruction (clinician-
rated) 
219 (42) 
Response to most recent line:  
CR 67 (13) 
PD 211 (41) 
PR 142 (28) 
SD 81 (16) 
Histopathology:  
Serous 375 (73) 
Other 141 (27) 
Grade:  
High (includes 2 and 3) 451 (91) 
Low 44 (9) 
Elevated CA125 459 (92) 
 
 
 
 
 
 
Table 2.  
 
mGPS Resistant/refractory 
N=316 
n(%) 
Potentially platinum 
sensitive N=200 
n(%) 
All 
N=516 
n(%) 
mPFS 
(months) 
mOS 
(months) 
0 157 (50) 125 (63) 282 
(55) 
5.3 18.1 
1 87 (28) 36 (18) 123 
(24) 
3.7 9.6 
2 72 (23) 39 (20) 111 
(22) 
2.9 6.6 
 
Table 3. Modified Glasgow Prognostic Score as a predictor of overall survival* 
mGPS HR (95% CI) p-
value 
Overall p-
value 
HR (95% CI) p-
value 
Overall p-
value 
0 1  <0.001* 1  0.024** 
1 1.58 (1.23-
2.03) 
<0.001  1.27 (0.94-1.70) 0.115  
2 2.47 (1.90-
3.21) 
<0.001  1.62 (1.14 – 
2.29) 
0.007  
*overall cox regression adjusted for ECOG PS and platinum resistance/sensitive 
**overall Cox regression adjusted for physical functioning, role functioning, global health status, abdominal/GI 
symptoms, haemoglobin, platinum resistance, symptomatic ascites, abdominal cramps, platelets, log CA125, 
neutrophil: lymphocyte<5, BMI, CA125 velocity≥5 
 
 
Table 4. Relationship between EORTC QLQ C-30 Global Health Status/Functional scales/OV28 Abdominal/GI symptoms and PS and mGPS 
 mGPS 
 0 1 2 All  
Domain Score ECOG N mean sd N mean sd N mean sd N mean sd p-value* 
Global health status score 0 130 65.3 20.5 27 56.2 20.0 16 53.1 20.8 173 62.7 20.9 0.006 
 1 126 57.1 20.4 75 57.8 23.0 67 41.8 21.4 268 53.5 22.4 <.001 
 2+ 14 39.3 23.7 15 42.2 23.0 25 42.7 22.6 54 41.7 22.6 0.670 
 All 270 60.1 21.5 117 55.4 22.8 108 43.7 21.8 495 55.4 22.8 <.001 
 p-value  <.001   0.133   0.201   <.001   
Role functional score 0 131 74.7 26.9 29 66.1 28.7 17 57.8 30.7 177 71.7 28.0 0.009 
 1 130 64.7 29.5 76 55.7 36.1 65 47.2 29.1 271 58.0 32.1 <.001 
 2+ 15 44.4 27.2 16 50.0 35.5 23 29.0 32.7 54 39.5 32.9 0.113 
 All 276 68.4 29.0 121 57.4 34.5 105 44.9 31.3 502 60.8 32.2 <.001 
 p-value  <.001   0.104   0.003   <.001   
Cognitive functional score 0 130 75.5 22.2 28 72.0 25.7 17 73.5 19.6 175 74.8 22.5 0.539 
 1 127 73.1 24.2 76 78.5 24.9 68 69.9 26.6 271 73.8 25.1 0.598 
 2+ 14 52.4 31.3 15 81.1 22.6 25 64.7 29.0 54 66.0 29.5 0.381 
 All 271 73.2 24.1 119 77.3 24.8 110 69.2 26.2 500 73.3 24.8 0.357 
 p-value  0.011   0.200   0.266   0.065   
Physical function score 0 130 78.5 18.1 29 72.1 22.6 17 69.0 22.5 176 76.5 19.6 0.023 
 1 130 68.7 19.3 76 65.5 23.8 68 55.4 22.4 274 64.5 22.0 <.001 
 2+ 15 50.2 18.0 16 52.9 19.1 25 42.3 28.8 56 47.4 23.8 0.245 
 All 275 72.3 19.9 121 65.4 23.5 110 54.5 25.1 506 66.8 23.1 <.001 
 p-value  <.001   0.011   <.001   <.001   
 mGPS 
 0 1 2 All  
Domain Score ECOG N mean sd N mean sd N mean sd N mean sd p-value* 
Emotional functional score 0 130 65.4 23.7 28 66.4 26.4 17 73.0 20.5 175 66.3 23.8 0.256 
 1 128 64.9 24.0 76 66.9 24.7 68 57.7 27.1 272 63.7 25.2 0.097 
 2+ 13 53.4 23.8 15 67.2 26.1 25 64.0 25.3 53 62.3 25.3 0.293 
 All 271 64.6 23.9 119 66.8 25.1 110 61.5 26.2 500 64.4 24.7 0.422 
 p-value  0.281   0.909   0.428   0.212   
Social functional score 0 130 69.4 28.3 28 67.3 28.1 17 70.6 24.0 175 69.1 27.7 0.988 
 1 128 65.4 29.4 76 64.5 32.1 67 56.2 30.4 271 62.9 30.6 0.063 
 2+ 13 48.7 29.2 15 66.7 28.9 25 50.7 30.2 53 54.7 30.0 0.896 
 All 271 66.5 29.1 119 65.4 30.6 109 57.2 29.9 499 64.2 29.8 0.010 
 p-value  0.031   0.867   0.042   0.001   
Abdominal/GI 0 130 24.8 21.0 28 32.9 21.6 17 32.2 21.7 175 26.8 21.3 0.054 
 1 129 34.1 23.7 76 35.2 22.1 66 45.4 23.1 271 37.1 23.5 0.003 
 2+ 15 39.7 26.5 16 34.1 20.1 24 46.6 23.7 55 41.1 23.7 0.288 
 All 274 30.0 23.1 120 34.5 21.6 107 43.6 23.3 501 34.0 23.4 <.001 
 p-value  <.001   0.793   0.073   <.001   
  
Table 5. Relationship between EORTC QLQ C-30 symptoms scales and PS and mGPS 
 mGPS 
 0 1 2 All  
Domain Score ECOG N mean sd N mean sd N mean sd N mean sd p-value* 
Fatigue 0 130 37.2 23.1 29 43.7 20.6 17 43.1 20.0 176 38.9 22.4 0.141 
 1 130 46.3 25.1 76 44.7 26.8 67 61.4 24.3 273 49.6 26.2 <.001 
 2+ 15 73.0 24.4 16 53.8 26.4 25 68.9 28.1 56 65.7 27.3 0.864 
 All 275 43.5 25.5 121 45.7 25.4 109 60.2 25.7 505 47.6 26.3 <.001 
 p-value  <.001   0.262   0.002   <.001   
Nausea / Vomiting 0 130 9.5 19.9 29 9.8 19.2 17 16.7 28.3 176 10.2 20.7 0.249 
 1 130 11.3 20.0 76 12.3 21.7 67 23.6 25.5 273 14.6 22.5 <.001 
 2+ 15 36.7 36.8 16 20.8 33.6 25 28.0 29.9 56 28.3 32.9 0.514 
 All 275 11.8 21.9 121 12.8 23.0 109 23.5 27.0 505 14.6 23.8 <.001 
 p-value  0.002   0.155   0.188   <.001   
Pain 0 130 26.5 27.0 29 39.7 31.6 17 42.2 28.9 176 30.2 28.5 0.006 
 1 130 33.5 28.2 76 40.6 31.2 68 49.8 30.9 274 39.5 30.4 <.001 
 2+ 14 53.6 40.9 16 40.6 36.0 25 39.3 34.3 55 43.3 36.4 0.270 
 All 274 31.2 29.0 121 40.4 31.7 110 46.2 31.5 505 36.7 30.8 <.001 
 p-value  0.001   0.906   0.611   <.001   
Dyspnoea 0 128 23.2 26.6 29 26.4 28.7 17 35.3 34.3 174 24.9 27.9 0.097 
 1 129 25.6 30.8 75 29.8 30.8 67 46.3 33.3 271 31.9 32.4 <.001 
 2+ 15 31.1 34.4 16 33.3 36.5 25 54.7 37.1 56 42.3 37.3 0.039 
 All 272 24.8 29.1 120 29.4 30.9 109 46.5 34.6 501 30.6 31.9 <.001 
 p-value  0.297   0.464   0.076   <.001   
 mGPS 
 0 1 2 All  
Domain Score ECOG N mean sd N mean sd N mean sd N mean sd p-value* 
Insomnia 0 129 28.2 30.5 29 37.9 30.5 17 25.5 25.1 175 29.5 30.1 0.681 
 1 130 38.2 30.8 76 38.2 35.6 67 47.3 31.9 273 40.4 32.6 0.090 
 2+ 15 46.7 35.2 16 39.6 37.0 25 50.7 34.9 56 46.4 35.2 0.638 
 All 274 33.9 31.3 121 38.3 34.3 109 44.6 32.5 504 37.3 32.5 0.004 
 p-value  0.002   0.891   0.023   <.001   
Appetite loss 0 130 17.7 24.3 29 19.5 20.9 17 27.5 31.7 176 18.9 24.6 0.148 
 1 130 25.4 31.3 76 24.1 30.6 66 44.9 35.3 272 29.8 33.1 <.001 
 2+ 15 53.3 35.2 16 47.9 40.3 25 65.3 32.6 56 57.1 35.8 0.237 
 All 275 23.3 29.5 121 26.2 31.1 108 46.9 35.9 504 29.0 32.7 <.001 
 p-value  <.001   0.009   <.001   <.001   
Constipation 0 130 19.7 29.8 29 32.2 37.2 17 31.4 34.3 176 22.9 31.9 0.043 
 1 130 27.4 33.8 75 21.3 30.8 67 33.3 37.2 272 27.2 34.1 0.408 
 2+ 15 44.4 41.1 15 11.1 16.3 24 27.8 38.9 54 27.8 36.5 0.263 
 All 275 24.7 32.9 119 22.7 31.6 108 31.8 36.9 502 25.8 33.6 0.123 
 p-value  0.004   0.029   0.704   0.199   
Diarrhoea 0 130 11.3 20.1 28 14.3 21.1 17 3.9 11.1 175 11.0 19.7 0.371 
 1 128 17.2 29.9 75 12.0 22.4 68 22.1 32.4 271 17.0 28.8 0.414 
 2+ 14 31.0 27.6 14 11.9 21.1 25 24.0 31.2 53 22.6 28.3 0.631 
 All 272 15.1 25.9 117 12.5 21.8 110 19.7 30.4 499 15.5 26.1 0.224 
 p-value  0.004   0.676   0.055   0.002   
 
 Figure 1. Kaplan-Meier curves showing OS and PFS by modified Glasgow Prognostic Score 
